 Mortality morbidity patients placebo Cardiac Arrhythmia Suppression Trial BACKGROUND AND METHODS Cardiac Arrhythmia Suppression Trial hypothesis suppression ventricular ectopy myocardial infarction incidence sudden death patients ventricular ectopy encainide moricizine active drug placebo use encainide flecainide excess mortality mortality morbidity randomization respective placebo RESULTS patients encainide placebo active drug flecainide placebo active drug mean follow-up months patients arrhythmia drug placebo nonarrhythmic cardiac causes drug placebo noncardiac causes drug placebo cardiac deaths due myocardial infarction shock patients drug placebo congestive heart failure drug placebo differences patients active drug placebo incidence nonlethal ventricular tachycardia proarrhythmia syncope permanent pacemaker congestive heart failure recurrent myocardial infarction angina coronary-artery bypass grafting angioplasty CONCLUSIONS excess deaths due deaths due acute recurrent myocardial infarction patients encainide flecainide Nonlethal events active-drug placebo groups mechanisms excess mortality treatment encainide flecainide unknown